Interferon for chronic hepatitis C in patients cured of malignancy

Eur J Pediatr. 1994 Sep;153(9):659-62. doi: 10.1007/BF02190687.

Abstract

Six patients with chronic hepatitis C who were cured of malignancy were treated with recombinant interferon-alpha at the dose of 4 MU/m2 for 12 months; the post-treatment follow up period was 12 months. Therapy was stopped within 6 months in three patients because of persistently abnormal alanine aminotransferase levels. In the remaining three patients, a complete normalization of alanine aminotransferase levels was obtained during treatment but it was not maintained after the end of interferon therapy. In addition, no patient cleared hepatitis C virus ribonucleic acid in serum. These results suggest that recombinant interferon is not effective in patients with chronic hepatitis C who were cured of a previous malignancy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Alanine Transaminase / blood
  • Child
  • Female
  • Hepatitis C / complications
  • Hepatitis C / enzymology
  • Hepatitis C / therapy*
  • Humans
  • Interferon Type I / therapeutic use*
  • Male
  • Neoplasms / complications
  • Pilot Projects
  • Recombinant Proteins
  • Treatment Outcome

Substances

  • Interferon Type I
  • Recombinant Proteins
  • Alanine Transaminase